Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Inclusion Criteria:

1. Age ≥ 18 years

2. Receiving anastrozole (1mg) or letrozole (2.5 mg) orally once a day, for ≥ 21 daysprior to registration and plan to continue it throughout the duration of study

3. Body Mass Index (BMI) between 18 and 35 kg/m^2

4. Women who have undergone a total mastectomy or breast conserving surgery for primarybreast cancer +/-chemo, +/-radiotherapy.

5. Must have BOTH ER and PR receptor-positive tumors and BOTH must be ≥26% positive.Alternatively, if ER and PR are determined by Allred score, the score needs to be 5or higher

6. Women who are postmenopausal by surgery, radiotherapy or presence of naturalamenorrhea ≥ 12 months

7. ≥ 5/10 arthralgia (in hands, wrist, knees, or hips) while being treated withanastrozole or letrozole which is felt by the patient to be caused by theiraromatase inhibitor as defined in the protocol. Note: Patients may, or may not, betaking non-opioid analgesics

8. Ability to complete questionnaire(s) by themselves or with assistance

9. ECOG Performance Status (PS) 0, 1 or 2

10. Willing to provide informed written consent

11. Willing to return to an Alliance enrolling institution for follow-up

12. Willing to provide blood samples for correlative research purposes

13. Laboratory values prior to registration as defined in the protocol:

14. Creatinine ≤1.5 x ULN

15. Hemoglobin > 11 g/dL

16. WBC > 3.0

17. Platelet Count > 100,000

18. SGOT (AST) ≤ 1.5 x ULN

Exclusion Criteria:

1. Presence of residual or recurrent cancer (locally or metastatic)

2. Diabetes mellitus or glucose intolerance, defined as a fasting glucose >125 mg/dL

3. History of coronary artery disease (angina or myocardial infarction)

4. Patients on hormone replacement therapy (HRT) ≤ 4 weeks prior to registration. Thisincludes the use of vaginal estrogen therapy.

5. Known hypersensitivity to any component of testosterone.

6. Prolonged systemic corticosteroid treatment, except for topical applications (e.g.for rash), inhaled sprays (e.g. for obstructive airway diseases), eye drops or localinsertion (e.g. intra-articular). Note: Short duration (< 2 weeks) of systemiccorticosteroids is allowed (e.g. for chronic obstructive pulmonary disease) but notwithin 30 days prior to registration.

7. Receiving any other investigational agent

8. History of a deep venous thrombosis or a thromboembolism

9. Concurrent use of the aromatase inhibitor exemestane, as it is structurally similarto an androgen

10. Concurrent radiation therapy or chemotherapy

11. Current or planned use of cyclosporine, anticoagulants, oxphenbutazone, insulin,oral or injectable vitamin D doses over 4,000IU/day, or tamoxifen